Application of a blood-derived enzymatic peptide in the preparation of drugs for inhibiting intestinal inflammation in animals

A technology of intestinal inflammation and blood-derived enzymes, applied in the field of biomedicine, can solve problems such as exacerbating drug residues, carcinogenesis, and human harm

Active Publication Date: 2021-08-31
福建蓝昊肽生物科技发展有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the process of livestock and poultry breeding, criminals ignore national laws and regulations and add clenbuterol to livestock and poultry feed, causing harm to the human body; in the process of livestock and poultry breeding, antibiotics such as chloramphenicol and terraforming Although it can effectively prevent antiseptic and antibacterial effects, some of the drug residues in the animal body cannot be metabolized in the body after ingestion, causing cancer and causing serious harm to the human body.
However, modern farming tends to be high-density and intensive farming, which makes the breeding body more susceptible to disease and further aggravates the problem of drug residues
However, the use of enzymatic peptides - enzymatic peptides from blood sources as a drug to inhibit intestinal inflammation in animals has not been reported in the literature so far.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of a blood-derived enzymatic peptide in the preparation of drugs for inhibiting intestinal inflammation in animals
  • Application of a blood-derived enzymatic peptide in the preparation of drugs for inhibiting intestinal inflammation in animals
  • Application of a blood-derived enzymatic peptide in the preparation of drugs for inhibiting intestinal inflammation in animals

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] 5.0 g of pig blood, 0.15 mg of trypsin, 0.15 mg of gastric protease, 40ml of phosphoric acid buffered solution in the cone bottle, enzymatic solution in the shaker. The shaker is set to 37 degrees, and the stirring speed is 150R / MIN, the enzymatic solution is 6 hours. The enzymatic hydrolyzate centrifugal was centrifuged, and the rotational speed of the centrifuge was set to 5000 rpm / min, and the centrifugal time was 10 min. Deeply precipitate, take it, repeat the centrifugation twice; the resulting filtrate vacuum filtrate, the resulting filtrate was filtered, the resulting filtrate was filtered twice, the enzymatic epoxine was filtered twice, and the ultrafiltration was removed (the pore diameter of 3000 Da) was 2500 rpm. / min centrifugally filtered 3000 Da or less filtration, and then lyophilized in a vacuum freeze dryer, and the blood source enzyme peptide powder was obtained. The acute intestinal inflammatory model of C57BL / 6 mice was established using DSS: usin...

Embodiment 2

[0026] 5.0 g of pig blood, 0.15 mg of trypsin, 0.15 mg of gastric protease, 40ml of phosphoric acid buffered solution in the cone bottle, enzymatic solution in the shaker. The shaker is set to 37 degrees, and the stirring speed is 150R / MIN, the enzymatic solution is 6 hours. The enzymatic hydrolyzate centrifugal was centrifuged, and the rotational speed of the centrifuge was set to 5000 rpm / min, and the centrifugal time was 10 min. Deeply precipitate, take it, repeat the centrifugation twice; the resulting filtrate vacuum filtrate, the resulting filtrate was filtered, the resulting filtrate was filtered twice, the enzymatic epoxine was filtered twice, and the ultrafiltration was removed (the pore diameter of 3000 Da) was 2500 rpm. / min centrifugally filtered 3000 Da or less filtration, and then lyophilized in a vacuum freeze dryer, and the blood source enzyme peptide powder was obtained. The acute intestinal inflammatory model of C57BL / 6 mice was established using DSS: usin...

Embodiment 3

[0039]5.0 g of pig blood, 0.15 mg of trypsin, 0.15 mg of gastric protease, 40ml of phosphoric acid buffered solution in the cone bottle, enzymatic solution in the shaker. The shaker is set to 37 degrees, and the stirring speed is 150R / MIN, the enzymatic solution is 6 hours. The enzymatic hydrolyzate centrifugal was centrifuged, and the rotational speed of the centrifuge was set to 5000 rpm / min, and the centrifugal time was 10 min. Deeply precipitate, take it, repeat the centrifugation twice; the resulting filtrate vacuum filtrate, the resulting filtrate was filtered, the resulting filtrate was filtered twice, the enzymatic epoxine was filtered twice, and the ultrafiltration was removed (the pore diameter of 3000 Da) was 2500 rpm. / min centrifugally filtered 3000 Da or less filtration, and then lyophilized in a vacuum freeze dryer, and the blood source enzyme peptide powder was obtained. The acute intestinal inflammatory model of C57BL / 6 mice was established using DSS: using...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of a blood-derived enzymatic hydrolysis peptide in the preparation of a drug for inhibiting intestinal inflammation in animals. Specifically, pig blood is used as a raw material and purified through grinding, enzymolysis, suction filtration, centrifugation, ultrafiltration and other processes to obtain A biologically active peptide that has the effect of inhibiting intestinal inflammation in animals. The dried active peptide is in the form of thin layer, powder, powder with lighter color. The biologically active peptide has the effect of inhibiting intestinal inflammation judged by its inhibitory effect on mouse intestinal inflammation, and can be used as feed, feed additive, pharmaceutical auxiliary material, etc. The blood-derived enzymatic peptide for inhibiting intestinal inflammation of the present invention is non-toxic and has no side effects, does not remain in animals, and has significant economic and social contributions. The invention will promote the rapid development of active peptide biological products in the pharmaceutical industry and the feed industry.

Description

Technical field [0001] The present invention belongs to the field of biopharmaceutical technology, and in particular, a blood source enzymatic hydrolyzide is used in the preparation of inhibiting animal intestinal inflammatory drugs. Background technique [0002] my country produces a large number of meat foods every year, including livestock and poultry, aquatic food, resulting in the main factors in my country's immortal food insecurity is the seriousness of the residue of veterinary drugs. During the process of livestock and poultry, the criminals ignore the national decree to add lean meat in livestock and poultry feed, which is harmful to the human body; in the process of livestock and poultry, it is used to prevent or treat diseases to use antibiotics such as chloramphenicol, soish Sui, etc., although it can effectively prevent corrosion and antibacterial effects, the residue of this drug in the animal, after intake the human body, some in the body cannot be met, carcinogen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/01A61P1/00A61P29/00A23K20/147C12P21/06
CPCA61K38/012A23K20/147C12P21/06
Inventor 吴文书李昊
Owner 福建蓝昊肽生物科技发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products